Report Summary

GBI Research, the leading business intelligence provider has released its latest research Antifungals Market to 2017 – Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth, which provides an insight into antifungals sales and price forecasts until 2017. The report examines the global antifungal therapies, treatment usage patterns and treatment flow algorithm. In addition, the geographical distribution of antifungal therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the Research and Development (R&D) pipeline and the potential future blockbusters until 2017 with in-depth analysis of the top three antifungal therapeutic indications, namely aspergillosis, dermatophytosis and candidiasis. Furthermore, it also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies is also presented. In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts. GBI Research analysis shows that the global antifungals market was estimated at $9.4 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 2.9% during 2002 and 2010. The antifungals market is dominated by generics. GBI Research forecasts that the market will grow at a CAGR of 1.9% during 2010-2017 to $10.8 billion. The patent expiry of a number of major drugs has paved way for the entry of generics. GBI Research analysis shows that the R&D pipeline for the antifungals market is not strong as it has become a generic market. Currently, only 38 molecules are in R&D, which indicates that antifungals R&D activity will not be very active for at least the next seven to eight years.

Scope

• Data and analysis on the antifungals market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
• Annualized market data for the antifungals market from 2002-2010 with forecasts to 2017.
• Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
• The competitive landscape of the global antifungals market including top companies’ benchmarking.
• Key M&A activities and licensing agreements that took place in 2009, 2010 and 2011 in the antifungals market.

Reasons to Buy

• Build effective strategies to launch their pipeline products by identifying potential geographies.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce safer and more efficacious first-in-class molecules.

Antifungals Market

Published: January 2012
No.OF Pages: 118
Price: Single User License – US$ 3500      Corporate User License US$ 10500

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8

2 Global Antifungals Market to 2017 – Introduction 10
2.1 Overview 10
2.2 GBI Research Report Guidance 11

3 Global Antifungals Market to 2017 – Market Characterization 12
3.1 Introduction 12
3.2 Different Classes of Antifungals 12
3.3 Forecast for Global Antifungals Market 13
3.3.1 Revenues 13
3.3.2 Branded and Generic Market Share 14
3.3.3 Annual Cost of Treatment (ACT) 15
3.3.4 Treatment Usage Patterns 16
3.4 Drivers for the Antifungals Market 20
3.4.1 Large Patient Population 20
3.4.2 Increase in Diagnosis Rate 20
3.5 Barriers for the Antifungals Market 21
3.5.1 Prominence of Generics in the Market 21
3.5.2 High Unmet Need in Case of Serious Invasive Fungal Infections 21

4 Global Antifungals Market – Geographical Landscape 22
4.1 Revenue Analysis by Geography 22
4.2 The US 22
4.2.1 Revenue 22
4.2.2 Annual Cost of Treatment 23
4.2.3 Treatment Usage Pattern 24
4.3 Top Five Countries of Europe 30
4.3.1 Revenue 30
4.3.2 Annual Cost of Treatment 31
4.3.3 Treatment Usage Pattern 32
4.4 Japan 38
4.4.1 Revenue 38
4.4.2 Annual Cost of Treatment 39
4.4.3 Treatment Usage Pattern 40

5 Global Antifungals Market – Aspergillosis Therapeutics Market 45
5.1 Introduction 45
5.2 Market Forecasts 45
5.3 Annual Cost of Treatment 46
5.3.1 Annual Cost of Treatment for Allergic Bronchopulmonary Aspergillosis 46
5.3.2 Annual Cost of Treatment for Invasive Aspergillosis 47
5.4 Treatment Usage Patterns 49
5.4.1 Diseased Population 50
5.4.2 Treatment Seeking Population 51
5.4.3 Diagnosed Population 52
5.4.4 Prescription Population 53
5.5 Treatment Flow Algorithm 54
5.5.1 Allergic Bronchopulmonary Aspergillosis 54
5.5.2 Invasive Aspergillosis 55
5.6 Branded and Generic Market Share 56
5.7 Major Marketed Products 56
5.7.1 Voriconazole (vfend) 57
5.7.2 Amphotericin B (amphocin) 57
5.7.3 AmBisome (amphotericin B) liposome for injection 57
5.7.4 Itraconazole (sporanox) 58
5.7.5 Caspofungin (cancidas) 58
5.7.6 Posaconazole (noxafil) 58
5.7.7 Prednisone (deltasone) 59

6 Global Antifungals Market – Dermatophytosis Therapeutics Market 60
6.1 Introduction 60
6.2 Market Forecasts 60
6.3 Annual Cost of Treatment 61
6.3.1 Annual Cost of Treatment for Tinea Cruris 61
6.3.2 Annual Cost of Treatment for Tinea Unguium (Onychomycosis) 62
6.3.3 Annual Cost of Treatment for Tinea Pedis 63
6.3.4 Annual Cost of Treatment for Tinea Capitis 65
6.3.5 Annual Cost of Treatment for Tinea Corporis 66
6.4 Treatment Usage Patterns 67
6.4.1 Diseased Population 68
6.4.2 Treatment Seeking Population 69
6.4.3 Diagnosed Population 70
6.4.4 Prescription Population 71
6.5 Treatment Flow Algorithm for Dermatophytosis 72
6.6 Branded and Generic Market Share 72
6.7 Major Marketed Products with Classification 73
6.7.1 Ketoconazole 2% cream (nizoral) 73
6.7.2 Clotrimazole 1% cream or lotion (lotrimin) 73
6.7.3 Econazole 1% cream or lotion (spectazole) 73
6.7.4 Miconazole 2% cream (monistat) 74
6.7.5 Terbinafine (lamisil) 74
6.7.6 Naftifine 1% cream (naftifin) 75
6.7.7 Griseofulvin 75
6.7.8 Itraconazole (sporanox) 75
6.7.9 Fluconazole (diflucan) 75
6.7.10 Sertaconazole nitrate cream (ertaczo) 76

7 Global Antifungals Market – Candidiasis Therapeutics Market 77
7.1 Introduction 77
7.2 Market Forecasts 77
7.3 Annual Cost of Treatment 78
7.3.1 Annual Cost of Treatment for Vaginal Candidiasis 78
7.3.2 Annual Cost of Treatment for Cutaneous Candidiasis 79
7.3.3 Annual Cost of Treatment for Oropharyngeal Candidiasis 80
7.3.4 Annual Cost of Treatment for Esophageal Candidiasis 82
7.3.5 Annual Cost of Treatment for Invasive Candidiasis 83
7.4 Treatment Usage Patterns 84
7.4.1 Diseased Population 85
7.4.2 Treatment Seeking Population 86
7.4.3 Diagnosed Population 87
7.4.4 Prescription Population 88
7.5 Treatment Flow Algorithm for Candidiasis 89
7.6 Branded and Generic Market Share 90
7.7 Major Marketed Products with Classification 90
7.7.1 Fluconazole 90
7.7.2 Itraconazole Oral Solution 91
7.7.3 Clotrimazole 91
7.7.4 Canestan 91
7.7.5 Anidulafungin (eraxis) 91
7.7.6 Nystatin Oral Suspension 92
7.7.7 Daktarin IV Solution 92

8 Global Antifungals Market – Pipeline Analysis 93
8.1 Introduction 93
8.2 Aspergillosis: Research and Development Pipeline 93
8.2.1 Overview 93
8.2.2 Phase lll 93
8.2.3 Phase ll 94
8.2.4 Phase l 94
8.2.5 Preclinical 94
8.2.6 Discovery 94
8.3 Dermatophytosis: Research and Development Pipeline 95
8.3.1 Overview 95
8.3.2 Phase lll 95
8.3.3 Phase ll 95
8.3.4 Phase l 95
8.3.5 Preclinical 95
8.4 Candidiasis: Research and Development Pipeline 96
8.4.1 Overview 96
8.4.2 Phase lll 96
8.4.3 Phase ll 96
8.4.4 Phase l 96
8.4.5 Preclinical 96
8.5 Profiles of Promising Drugs in the Antifungals Market 97
8.5.1 Eraxis + Vfend 97
8.5.2 Isavuconazole 97
8.5.3 NAFT-500 98
8.5.4 Fluconazole 98
8.5.5 Lavender Vaginal Cream 98

9 Global Antifungals Market – Competitive Landscape 99
9.1 Company Profiles 99
9.1.1 Ferrer Internacional S.A. 99
9.1.2 BioDelivery Sciences International, Inc. 100
9.1.3 Pfizer Inc. 101
9.1.4 Merck & Co Inc 102
9.1.5 Astellas Pharma Inc 103

10 Global Antifungals Market – Strategic Consolidations 105
10.1 Mergers and Acquisitions 105
10.1.1 Overview 105
10.1.2 Major Mergers and Acquisitions Deals 105
10.1.3 M&A by Year 105
10.1.4 M&A by Deal Value 106
10.1.5 M&A by Geography 106
10.2 Co-Development Deals 107
10.2.1 Overview 107
10.2.2 Major Co-Development Deals 107
10.3 Licensing Deals 107
10.3.1 Overview 107
10.3.2 Major Licensing Deals 107
10.3.3 Licensing Deals by Year 108

11 Global Antifungals Market – Appendix 111
11.1 Market Definitions 111
11.2 Abbreviations 111
11.3 Research Methodology 112
11.3.1 Coverage 113
11.3.2 Secondary Research 113
11.3.3 Primary Research 113
11.4 Therapeutic Landscape 114
11.4.2 Market Size by Geography 116
11.5 Geographical Landscape 117
11.6 Pipeline Analysis 117
11.7 Competitive Landscape 117
11.7.1 Expert Panel Validation 117
11.8 Contact Us 117
11.9 Disclaimer 117
11.10 Sources 118

1.1 List of Tables and Figures